Markets
Still life of a bottle of the new Wegovy semaglutide tablets on a womans hand.
(Michael Siluk/UCG/Universal Images Group via Getty Images)
GLUTIDE TURNED

Novo Nordisk has lost most of its post-Wegovy market cap gains

A weak sales outlook and a copycat scare capped a brutal week for Europe’s one-time most valuable company.

Hyunsoo Rim

Danish pharma giant Novo Nordisk has now erased nearly all of the market cap gains it racked up after winning FDA approval for its weight-loss drug Wegovy in 2021.

The company’s shares slid ~20% last week amid two major setbacks. On Tuesday, Novo warned that 2026 sales could fall by as much as 13%, citing “unprecedented pricing pressure” in the US, intensifying competition, and a looming patent expiry for semaglutide, the active ingredient in its GLP-1 drugs.

Then, telehealth company Hims & Hers launched a copycat version of Novo’s newly approved Wegovy pill on Thursday at an initial price of just $49 a month... though later that day, the FDA warned of a crackdown on “illegal copycat drugs.” Hims pulled the pill on Saturday. Novo’s shares were higher this morning as the company announced that it’s suing Hims.

Even so, the hits wiped out Novo’s January rebound, fueled by excitement around its oral pill launch. Zoom out further and the picture is even starker: almost all of Novo’s gains since Wegovy burst onto the scene are now gone.

Since its FDA approval in June 2021, Wegovy, alongside its diabetes-treating counterpart Ozempic, helped propel Novo to become Europe’s most valuable company, with its market cap peaking at ~$650 billion in mid-2024.

But that dominance didn’t last. Shortages of semaglutide left room for cheaper compounded alternatives from companies like Hims. Meanwhile, competitor Eli Lilly surged ahead after launching its weight-loss drug Zepbound in late 2023 — momentum that briefly pushed Lilly’s valuation above $1 trillion last November. By contrast with Novo, Lilly posted stronger-than-expected 2026 guidance last week, as its GLP-1s have been more effective than Novo's offerings, while also being cost-competitive.

After the weight-loss saga’s dramatic turn this weekend, however, Novo might still have some breathing room.

More Markets

See all Markets
markets

United beats Q1 earnings and revenue estimates, lowers full-year profit guidance amid surging jet fuel prices

United Airlines reported its first-quarter earnings results after the bell on Tuesday. The carrier’s shares ticked down in after-hours trading.

For Q1, United reported:

  • Adjusted earnings of $1.19 per share, compared to the Wall Street estimate of $1.08 per share compiled by FactSet.

  • $14.6 billion in revenue, compared to the $14.39 billion consensus estimate.

In the first quarter, United’s fuel expense grew 12.6% from the same period last year to $3.04 billion.

For the second quarter, United expects adjusted earnings per share of between $1 and $2, shy of Wall Street expectations of $2.08. For the full year ahead, United said it expects earnings between $7 and $11 per share, compared to its prior guidance of between $12 and $14 per share.

“Guidance assumes United’s revenue recovers 40% to 50% of the fuel price increases in the second quarter, 70% to 80% of the fuel price increases in the third quarter and 85% to 100% of the fuel price increases in the fourth quarter 2026,” read the company’s investor update.

Earlier this month, United was among the first major US airlines to hike its bag fees amid higher fuel costs. Its shares have fallen more than 15% from a February high days before the war in Iran began.

United has also made waves this month following reports that CEO Scott Kirby had floated the idea of a merger with American Airlines to President Trump. A merger between two of the big four airlines would create a true US behemoth, controlling more than a third of the American market. American Air last week said it wasn’t interested in merging with United and hadn’t held talks on the idea. On Tuesday, Trump told CNBC that he doesn’t like the idea either.

markets

Hedge funds are following retail traders into the Magnificent 7

Hedge funds are following retail traders into the stocks the masses never stopped buying.

“As we kick off earnings for megacap tech stocks, this stood out: [hedge funds] have started buying Mag7 stocks again this month though positioning remains well below the peak levels seen in early 2016,” wrote Goldman Sachs’ Cullen Morgan.

Goldman PB Mag 7
Source: Goldman Sachs

In early April, JPMorgan strategist Arun Jain noted that retail investors had basically been selling everything but the Magnificent 7 stocks as part of a more cautious stance due to the Iran war.

(Apple has been a long-standing exception to this trend, presumably because retail traders arent fond of its hands-off approach to AI.)

JPM Retail flows

Last August, Jain discussed how retail activity tended to “crowd in” institutional buyers in meme stocks, while Goldman’s John Marshall advised clients to piggyback on stocks beloved by retail traders. Speculative, retail-geared assets proceeded to go on a tremendous run that soured in October.

But there are some early indications that a similar bout of speculative fervor is bubbling up once more.

markets

POET Technologies surges above $10 for first time in 4 years amid explosion in call volumes

POET Technologies is up nearly 40% this week as options market activity goes haywire in a faint echo of what got the stock on retail traders’ radars in October.

As of 11:12 a.m. ET, more than 10 calls have changed hands for every put traded. This bullish impulse has propelled the stock above the $10 threshold for the first time since March 2022.

Shares of the optical communications firm briefly dipped last week after Wolfpack Research said it was short the company because its investors would be exposed to an “IRS tax nightmare.”

The company responded that day saying it was taking measures for US shareholders that “should mitigate certain potential adverse US federal income tax consequences to it that could otherwise result from the Company’s status as a passive foreign investment company.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.